创新链/学科链/研发链/产业链

新药研发前沿动态 / 医药领域趋势进展

柳梦媛, 徐晨, 姚文兵, 田浤. 口服多肽和蛋白质药物的研究进展[J]. 药学进展, 2021, 45(6): 452-459.
引用本文: 柳梦媛, 徐晨, 姚文兵, 田浤. 口服多肽和蛋白质药物的研究进展[J]. 药学进展, 2021, 45(6): 452-459.
LIU Mengyuan, XU Chen, YAO Wenbing, TIAN Hong. Research Progress of Oral Peptide and Protein Drugs[J]. Progress in Pharmaceutical Sciences, 2021, 45(6): 452-459.
Citation: LIU Mengyuan, XU Chen, YAO Wenbing, TIAN Hong. Research Progress of Oral Peptide and Protein Drugs[J]. Progress in Pharmaceutical Sciences, 2021, 45(6): 452-459.

口服多肽和蛋白质药物的研究进展

Research Progress of Oral Peptide and Protein Drugs

  • 摘要: 多肽和蛋白质药物由于其特异性高、安全性高的特点已广泛应用于各种疾病的临床治疗,但其主要给药途径是注射给药,降低了患者的依从性。口服作为一种安全性高、依从性强的给药途径逐渐成为研究焦点,但胃肠道的结构组织和生理功能使得多肽和蛋白质药物口服后生物利用度低、半衰期短。口服后多肽和蛋白质药物的吸收成为此类药物口服给药途径开发的瓶颈,但随着技术的发展,近年来对促进多肽和蛋白质药物口服吸收的研究在临床前和临床试验方面均取得较大进展。综述多肽和蛋白质药物口服吸收途径、影响因素、提高多肽和蛋白质药物口服吸收的方法以及相关临床试验的研究进展。

     

    Abstract: Peptides and protein drugs have been widely used in clinical practice, with advantages of high specificity, safety and activity. However, these drugs still require parenteral administration, which can be a deterrent to medication compliance. There is a growing interest in oral delivery due to its high safety and good compliance, but it faces tremendous challenges of low bioavailability and short half-life, which are related to structural organization and physiological function of the gastrointestinal tract. The poor bioavailability of peptides and protein drugs has become a bottleneck in the development of oral drug delivery pathways of such drugs. However, with the development of technology, the research on the promotion of the oral absorption of peptides and protein drugs has achieved much progress in preclinical and clinical trials in recent years. This paper reviews recent advances in research on absorption pathways of peptides and protein drugs, influence factors, strategies to promote their oral absorption as well as related clinical trials.

     

/

返回文章
返回